Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy Adults
NCT05408312Phase 1Completed
- Sponsor
- Serum Institute of India
- Start
- Jun 2022
- Primary completion
- Feb 2024
- Modality
- Prophylactic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NVSI-06-08 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Serum Institute of India. Primary endpoints: Incidence rate of any adverse reactions/events within 30 minutes after vaccination, Incidence severity of any adverse reactions/events within 30 minutes after vaccination and 13 more. Started Jun 2022; status: completed.
02
Drugs
NVSI-06-08
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05408312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05408312.